1. Evolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National Registry
- Author
-
Balaz, David, Wikman Jorgensen, Philip Erick, Galvañ, Vicente Giner, Rubio Rivas, Manuel, de Miguel Campo, Borja, López, Mariam Noureddine, López Caleya, Juan Francisco, Huelgas, Ricardo Gómez, Pesqueira Fontán, Paula María, Bailón, Manuel Méndez, Fernández Garcés, Mar, Fernández Cruz, Ana, García García, Gema María, Rhyman, Nicolás, Corral Gudino, Luis, Rodríguez Mancheño, Aquiles Lozano, De La Chica, María Navarro, Torregrosa García, Andrea, Alcalá, José Nicolás, Díaz Jiménez, Pablo, Royo Trallero, Leticia Esther, Comas Casanova, Pere, Núñez Cortés, Jesús Millán, Casas Rojo, José-Manuel, Balaz, David, Wikman Jorgensen, Philip Erick, Galvañ, Vicente Giner, Rubio Rivas, Manuel, de Miguel Campo, Borja, López, Mariam Noureddine, López Caleya, Juan Francisco, Huelgas, Ricardo Gómez, Pesqueira Fontán, Paula María, Bailón, Manuel Méndez, Fernández Garcés, Mar, Fernández Cruz, Ana, García García, Gema María, Rhyman, Nicolás, Corral Gudino, Luis, Rodríguez Mancheño, Aquiles Lozano, De La Chica, María Navarro, Torregrosa García, Andrea, Alcalá, José Nicolás, Díaz Jiménez, Pablo, Royo Trallero, Leticia Esther, Comas Casanova, Pere, Núñez Cortés, Jesús Millán, and Casas Rojo, José-Manuel
- Abstract
Objectives: Since the results of the RECOVERY trial, WHO recommendations about the use of corticosteroids (CTs) in COVID-19 have changed. The aim of the study is to analyse the evolutive use of CTs in Spain during the pandemic to assess the potential influence of new recommendations. Material and methods: A retrospective, descriptive, and observational study was conducted on adults hospitalised due to COVID-19 in Spain who were included in the SEMI-COVID-19 Registry from March to November 2020. Results: CTs were used in 6053 (36.21%) of the included patients. The patients were older (mean (SD)) (69.6 (14.6) vs. 66.0 (16.8) years; p < 0.001), with hypertension (57.0% vs. 47.7%; p < 0.001), obesity (26.4% vs. 19.3%; p < 0.0001), and multimorbidity prevalence (20.6% vs. 16.1%; p < 0.001). These patients had higher values (mean (95% CI)) of C-reactive protein (CRP) (86 (32.7–160) vs. 49.3 (16–109) mg/dL; p < 0.001), ferritin (791 (393–1534) vs. 470 (236–996) µg/dL; p < 0.001), D dimer (750 (430–1400) vs. 617 (345–1180) µg/dL; p < 0.001), and lower Sp02/Fi02 (266 (91.1) vs. 301 (101); p < 0.001). Since June 2020, there was an increment in the use of CTs (March vs. September; p < 0.001). Overall, 20% did not receive steroids, and 40% received less than 200 mg accumulated prednisone equivalent dose (APED). Severe patients are treated with higher doses. The mortality benefit was observed in patients with oxygen saturation
- Published
- 2021